rethinkTHC Search
Menu
Study breakdown

Targeting the Endocannabinoid System May Help Social Withdrawal in Schizophrenia

PreclinicalPreliminary evidence
The takeaway

A drug that boosts endocannabinoid levels reversed social withdrawal in a rat model of schizophrenia, with the insular cortex identified as a key brain region.

Psychiatry researchers, schizophrenia drug developers, endocannabinoid system neuroscientists

What the researchers found

The FAAH inhibitor URB597 reversed social withdrawal in PCP-treated rats (a schizophrenia model) but decreased social interaction in healthy controls. The agranular insular cortex emerged as a key neural substrate — pCREB levels in this region positively correlated with social interaction time (r=0.43).

Why it matters

Social withdrawal is one of the most debilitating symptoms of schizophrenia and has no effective treatment. This study identifies both a therapeutic target (endocannabinoid system) and a brain region (insular cortex) that could guide drug development.

The numbers in context

Six cortical regions analyzed. Agranular insular cortex pCREB correlated with social interaction (r=0.43, p<0.05). URB597 reversed social deficits in PCP-treated rats but reduced social behavior in healthy controls, showing state-dependent effects.

How the study worked

Rats were treated with PCP (schizophrenia model) or saline, then received FAAH inhibitor URB597 or vehicle. Social interaction was measured, and CREB/pCREB expression was analyzed in six prefrontal and insular cortical regions using immunohistochemistry.

What this study cannot tell us

PCP model captures some but not all aspects of schizophrenia. Small sample sizes limit statistical power. Single-dose acute treatment — chronic effects unknown. Rat social behavior is a limited proxy for human social functioning.

How to read the evidence

Single preclinical study with small sample sizes provides mechanistic insights but requires replication and clinical translation.

When this study was published

Published 2026, contributing to growing endocannabinoid-schizophrenia research.

The bigger picture

The negative symptoms of schizophrenia — social withdrawal, flat affect, lack of motivation — remain the greatest unmet need in psychiatry. The endocannabinoid system's state-dependent effects (helping when impaired, not when normal) make it an unusually promising target.

Questions still open

  • Why does URB597 improve social behavior in the disease state but worsen it in healthy animals? Could FAAH inhibitors be developed specifically for schizophrenia's negative symptoms? What role does the insular cortex play in human social withdrawal?

Common questions

Could cannabis-related drugs help with schizophrenia symptoms?
A drug that boosts the body's own endocannabinoids (by blocking the enzyme FAAH) reversed social withdrawal in a rat model of schizophrenia — but importantly, this is not about cannabis itself, and cannabis use is generally not recommended for people with schizophrenia.
Why did the drug work differently in healthy vs. sick animals?
URB597 improved social behavior in schizophrenia-model rats but actually reduced it in healthy rats, suggesting the endocannabinoid system has different roles depending on brain state — which could allow targeted treatment of specific symptoms.

Read the original research

Inhibition of Fatty Acid Amide Hydrolase Alters Cortical CREB Signaling and Social Behavior in a Rat Model of Schizophrenia.

The European journal of neuroscience, 63(3), e70427

Citation

Kumar, Aditya; Seillier, Lenka; Kuchař, Martin; Seillier, Alexandre. (2026). Inhibition of Fatty Acid Amide Hydrolase Alters Cortical CREB Signaling and Social Behavior in a Rat Model of Schizophrenia.. The European journal of neuroscience, 63(3), e70427. https://doi.org/10.1111/ejn.70427

Explore the wider topic